Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age50-69
SponsorFundacion Clinic per a la Recerca Biomédica

About this trial

Study to evaluate the efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men and women aged 50 to 69.

Have participated in the early detection program for colorectal cancer.

Positive result in the fecal occult blood test (≥20 μg Hb/g feces).

Scheduled screening colonoscopy at Hospital Clínic de Barcelona.

Disqualifiers

Severe renal failure (grade IV or V) (Annex 6, Stages of Renal Impairment) and/or congestive heart failure (New York Heart Association Scale Class III and IV) (Annex 7, NYHA Scale).

Colonoscopy within the last year.

Barthel Index of <20 (Annex 5, Barthel Index) and who also meet the Rome IV Criteria for the diagnosis of functional constipation (Annex 8, Rome IV Criteria).

Mental disability or severe mental disorder (schizophrenia and other psychotic disorders, recurrent severe major depressive disorders, severe obsessive-compulsive disorder, severe personality disorders, and bipolar disorders).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Clensia®

    Drug

    Participants will take the treatment in two doses, 4 sachets dissolved in 200cc of water 9-12 hours before the examination and 4 sachets dissolved in 200cc of water 4 hours before the examination.

  • Citrafleet®

    Drug

    Participants will take the treatment in two doses, 1 sachet dissolved in 200cc of water 9-12 hours before the examination and 1 sachet dissolved in 200cc of water 4 hours before the examination.

Treatment groups

818 Participants
are divided into 2 treatment groups
Group A: Clensia®Experimental treatment 1 intervention
Group B: Citrafleet®Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Adenoma detection rate

Adenoma detection rate, defined as the proportion of patients with at least one adenoma in relation to the total number of subjects in each study group (Clensia® Group (Group A); Citrafleet® Group (Group B)).

Time frame
week 2 (Colonoscopy visit)

Secondary outcomes

1

Lesion detection rate

Lesion detection rate, defined as the proportion of patients with at least one polyp in relation to the total number of subjects in each group.

Time frame
week 2 (Colonoscopy visit)
2

Adenomas per colonoscopy

Adenomas per colonoscopy, defined as the mean number of adenomas detected by colonoscopy in the subjects in each group.

Time frame
week 2 (Colonoscopy visit)
3

Presence of foam

The presence of foam using the CEBuS (Colon Endoscopic Bubble Scale), in which each colonic segment (right colon, transverse colon, left colon) is scored from 0 to 2 (0=no or minimal number of bubbles; 1=moderate amount of bubbles affecting 5-50% of the circumference, affecting the vision of the mucosa and requiring additional time to wash; 2=abundant bubbles occupying \>50% of the circumference, obscuring the mucosa and require ring additional time to washing).

Time frame
week 2 (Colonoscopy visit)
4

Presence of bubbles

The presence of bubbles using the CEBuS (Colon Endoscopic Bubble Scale), in which each colonic segment (right colon, transverse colon, left colon) is scored from 0 to 2 (0=no or minimal number of bubbles; 1=moderate amount of bubbles affecting 5-50% of the circumference, affecting the vision of the mucosa and requiring additional time to wash; 2=abundant bubbles occupying \>50% of the circumference, obscuring the mucosa and require ring additional time to washing).

Time frame
week 2 (Colonoscopy visit)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.